Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 08 Mar 2023
3-year results show that patients who underwent low-risk aortic valve replacement continue to report lower rates of all-cause mortality and stroke with TAVI compared to surgery
Read Full NewsA groundbreaking study reveals that combining ixekizumab and tirzepatide significantly improves outcomes for adults with psoriatic arthritis and obesity.
Coya Therapeutics reveals promising results for COYA 302, a potential treatment for frontotemporal dementia, showing cognitive stability and Treg enhancement.
Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on the International Stroke Conference (ISC)!
Here's some of what is coming soon to NeurologyLive® this week.
FDA Clears LEADOPTIK's LIA System for Higher-Accuracy Lung Biopsy
1.
Trial Questions Role of Dual Immunotherapy in First-Line NSCLC
2.
The Early Progression of Prostate Cancer Is Not Stopped by Metformin.
3.
Three Cycles of Chemo Noninferior to Six for Rare Childhood Eye Cancer
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
Even a few mutated cells can significantly impact how blood cancers develop, study finds
1.
A Closer Look at MCV Modules: Features, Functions, and Benefits
2.
Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients
3.
Biomimetic Nanovesicles for Breast Cancer: Targeting Senescence to Overcome Chemoresistance
4.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
5.
7 Subtle Signs of Leukemia: How to Spot the Symptoms Early
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Managing CNS diseases at the point of diagnosis in ALK + NSCLC
2.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
3.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective
4.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
5.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge